	US 12,077,518 B2
	Nicotine salts, co-crystals, and salt co-crystal complexes
Gary M. Dull, Lewisville, NC (US); Andrew Carr, Cambridge (GB); and Emma Sharp, Cambridgeshire (GB)
Assigned to R.J. Reynolds Tobacco Company, Winston-Salem, NC (US)
Filed by R.J. Reynolds Tobacco Company, Winston-Salem, NC (US)
Filed on Nov. 10, 2020, as Appl. No. 17/094,572.
Application 15/886,496 is a division of application No. 14/951,939, filed on Nov. 25, 2015, granted, now 9,896,429, issued on Feb. 20, 2018.
Application 17/094,572 is a continuation of application No. 16/598,417, filed on Oct. 10, 2019, granted, now 10,865,192.
Application 16/598,417 is a continuation of application No. 15/886,496, filed on Feb. 1, 2018, granted, now 10,464,917, issued on Nov. 5, 2019.
Application 14/951,939 is a continuation in part of application No. 14/721,283, filed on May 26, 2015, granted, now 9,738,622, issued on Aug. 22, 2017.
Claims priority of provisional application 62/003,295, filed on May 27, 2014.
Prior Publication US 2021/0122728 A1, Apr. 29, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 401/04 (2006.01); A24B 13/00 (2006.01); A24B 15/24 (2006.01); A24F 40/20 (2020.01); A61K 9/00 (2006.01); C07C 57/15 (2006.01); C07D 239/52 (2006.01); A24F 40/10 (2020.01); A24F 40/40 (2020.01); A61M 11/04 (2006.01); A61M 15/06 (2006.01)

CPC C07D 401/04 (2013.01) [A24B 13/00 (2013.01); A24B 15/243 (2013.01); A24F 40/20 (2020.01); C07C 57/15 (2013.01); C07D 239/52 (2013.01); A24F 40/10 (2020.01); A24F 40/40 (2020.01); A61K 9/0056 (2013.01); A61K 9/0073 (2013.01); A61M 11/042 (2014.02); A61M 15/06 (2013.01); A61M 2205/8206 (2013.01)]

27 Claims

1. An oral product comprising a salt of nicotine and fumaric acid, wherein the salt is a non-solvated mono-salt, characterized by an X-ray powder diffraction pattern having peaks at one or more of the following 2-theta diffraction angles: 14.9, 18.4, 19.9, and 22.4.